MannKind Corp - Asset Resilience Ratio
MannKind Corp (MNKD) has an Asset Resilience Ratio of 7.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MNKD net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how MannKind Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of MannKind Corp.
Liquid Assets Composition Over Time
This chart breaks down MannKind Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of MannKind Corp's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $58.20 Million | 7.95% |
| Total Liquid Assets | $58.20 Million | 7.95% |
Asset Resilience Insights
- Limited Liquidity: MannKind Corp maintains only 7.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
MannKind Corp Industry Peers by Asset Resilience Ratio
Compare MannKind Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for MannKind Corp (2002–2025)
The table below shows the annual Asset Resilience Ratio data for MannKind Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.18% | $96.46 Million | $792.18 Million | -26.14pp |
| 2024-12-31 | 38.32% | $150.92 Million | $393.84 Million | +26.40pp |
| 2023-12-31 | 11.91% | $56.62 Million | $475.20 Million | -22.32pp |
| 2022-12-31 | 34.23% | $101.08 Million | $295.28 Million | +9.34pp |
| 2021-12-31 | 24.89% | $79.93 Million | $321.16 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $108.61 Million | -- |
| 2019-12-31 | 21.32% | $19.98 Million | $93.72 Million | +15.63pp |
| 2017-12-31 | 5.69% | $4.81 Million | $84.58 Million | +5.36pp |
| 2016-12-31 | 0.33% | $350.00K | $107.06 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $126.41 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $394.44 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $258.65 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $251.31 Million | -- |
| 2011-12-31 | 0.26% | $515.00K | $199.55 Million | -1.32pp |
| 2010-12-31 | 1.58% | $4.37 Million | $277.26 Million | +0.58pp |
| 2009-12-31 | 1.00% | $2.48 Million | $247.40 Million | -5.67pp |
| 2008-12-31 | 6.67% | $18.84 Million | $282.46 Million | -14.99pp |
| 2006-12-31 | 21.66% | $116.92 Million | $539.74 Million | -17.57pp |
| 2005-12-31 | 39.23% | $89.60 Million | $228.37 Million | +32.17pp |
| 2004-12-31 | 7.06% | $11.55 Million | $163.48 Million | +5.61pp |
| 2003-12-31 | 1.45% | $1.82 Million | $125.88 Million | -9.18pp |
| 2002-12-31 | 10.63% | $11.13 Million | $104.77 Million | -- |
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more